I highly doubt that - any continued dosing from Phase IIb for participants post their trial if they decide to continue it in 18-24 months time would be separated the data wouldn't be released until after completion of the trial. It would just make the trial messy it would be under a separate protocol. I'd also assume it wont be a straight continuation as with the last trial the last time point measured is 4 & 8 week post treatment.
I highly doubt that - any continued dosing from Phase IIb for...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $68.51M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45000 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 40689 | 1 |
View Market Depth
| Last trade - 07.31am 19/04/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable